XML 20 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Assets:    
Cash and cash equivalents $ 12,945 $ 9,408
Investments 2,778 3,117
Accounts receivable, net 27,276 24,431
Inventories 19,090 17,760
Assets held for sale 908 0
Other current assets 2,685 5,292
Total current assets 65,682 60,008
Long-term investments 21,096 23,025
Property and equipment, net 12,873 12,896
Operating lease right-of-use assets 17,872 19,122
Goodwill 78,150 79,121
Intangible assets, net 24,754 29,026
Separate accounts assets 3,228 5,087
Other assets 4,620 4,714
Total assets 228,275 232,999
Liabilities:    
Accounts payable 14,838 12,544
Pharmacy claims and discounts payable 19,423 17,330
Health care costs payable 10,406 8,808
Policyholders’ funds 1,500 4,301
Accrued expenses 18,745 17,670
Other insurance liabilities 1,140 1,303
Current portion of operating lease liabilities 1,678 1,646
Current portion of long-term debt 1,778 4,205
Liabilities held for sale 228 0
Total current liabilities 69,736 67,807
Long-term operating lease liabilities 16,800 18,177
Long-term debt (1) 50,476 51,971
Deferred income taxes 3,880 6,270
Separate accounts liabilities 3,228 5,087
Other long-term insurance liabilities 6,108 6,402
Other long-term liabilities 6,732 1,904
Total liabilities 156,960 157,618
Commitments and contingencies (Note 16)
Shareholders’ equity:    
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding 0 0
Common stock, par value $0.01: 3,200 shares authorized; 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and capital surplus 48,193 47,377
Treasury stock, at cost: 458 and 422 shares at December 31, 2022 and 2021 (31,858) (28,173)
Retained earnings 56,145 54,906
Accumulated other comprehensive income (loss) (1,465) 965
Total CVS Health shareholders’ equity 71,015 75,075
Noncontrolling interests 300 306
Total shareholders’ equity 71,315 75,381
Total liabilities and shareholders’ equity $ 228,275 $ 232,999